Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026

Liquid Biopsy Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies.
Liquid biopsy helps in collection of a wide range of information about a cancer/tumor
through a simple blood sample. The procedure can help in exact detection of mutations
in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC).
Furthermore, identification of traces of the cancer’s DNA in the blood could help in
administration of precision treatments that could increase the probability of treatment
effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally
invasive method can be performed with 5 milliliters of blood which would detect present
state of metastases in various tumors. The liquid biopsy process is witnessing increasing
adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is
expected to emerge as a game changer in the field of oncology in the forthcoming years.
Liquid Biopsy Market: Drivers and Restraints
Foremost drivers for the liquid biopsy market include. Factors such as tolerability and
patient convenience are promoting adoption of liquid biopsies. Liquid biopsy procedures
are replacing tissue diagnosis procedures which often is not possible through tissue
biopsy in cases of non-small cell lung cancers. Clinical trial conducted by the companies
have been noted that the liquid biopsies could also help in detection of cancer in its early
stage of than arrival of particular symptoms. This could lead to provision of a longer
treatment horizon and better chances of elongating the survival period of the patient.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1396
Report
Description
Report Description
Lack of documented evidence about the efficacy of the process, cost-intensive nature of
the research process that leads to frequent clinical trial abandonment and dearth of
people with specialized knowledge on the same are the factor hindering the growth of
liquid biopsy market. Countries with limited capital investment in R&D infrastructure and
dearth of skilled professionals, would largely influences the development pace of the
technology and thus its establishment as a preferred biopsy method.
Liquid Biopsy Market: Segmentation
Biosimilars and Follow-on Biologics Market can be segmented into these following ways:
• Segmentation by approach of diagnosis
• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (ctDNA)
• RNA in exosomes
• Extra-cellular vesicles (EVs)
• Segmentation by type of cancer application
• Lung cancer
• Pancreatic cancer
• Leukemia
• Other visceral (deeply located) cancers
Report
Description
Report Description
•Segmentation by channel participants
• Cancer Centers and Hospitals
• Contract Research Organizations
• Academic Institutions
• Specialized research laboratories
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1396
Liquid Biopsy Market: Overview
The revolutionary nature of liquid biopsy procedure is expected to create noise in the
field of tissue biopsy and innovative cancer diagnosis in near future. Large drug makers
are increasing entering into collaborative partnerships with leading academic institutions
such as Dana Farber Cancer Research Institute, University of Oxford, U.S. National Cancer
Institute, and others to increase the rapidity of research in liquid biopsy. The current
prospect of the market is however limited to developed countries in the world but is
expected to exhibit significantly high CAGR over a ten-year forecast period.
Liquid Biopsy Market: Region-wise Outlook
Depending on geographic regions, liquid biopsy market is segmented into seven key
regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific,
Japan, and Middle East & Africa. All major action in the field of liquid biopsy is expected
to emerge from North America and Europe region over the forecast period.
Report
Description
Report Description
However, with development of sophisticated R&D infrastructure in emerging region such
as APAC, is expected to gain traction supported through gradual availability of low-cost
meaningful liquid biopsy option in cancer diagnosis. Other factors expected to prominent
impact on the growth of liquid biopsy are increasing patient awareness and affordability
levels & regulatory harmonization. However, increasing funding for private public
partnerships in field of cancer research is expected to fuel the adoption of liquid biopsy
over the forecast period. Moreover, the rising disease incidence of lung and pancreatic
cancer in all major regions of the world is expected to drive the growth of liquid biopsy
market.
Browse full report: http://www.futuremarketinsights.com/reports/liquid-biopsy-market
Liquid Biopsy Market: Key Players
Some of the key players in the liquid biopsy market are Janssen Diagnostics, Qiagen,
Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal
Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome
Sciences, and HansaBiomed OU among others.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705